Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547674 | 0.88 | HSD11B1 (0.53) | HSD11B1ALDH1A1HSD17B10SMN1; SMN2MAPT | |
| SCHEMBL1702686 | 0.88 | HSD11B1 (0.50) | HSD11B1ALDH1A1HSD17B10SMN1; SMN2MAPT | |
| SCHEMBL1493404 | 0.79 | HSD11B1 (0.64) | HSD11B1ALDH1A1HSD17B10MAPTHDAC6 | |
| SCHEMBL1493377 | 0.79 | HSD11B1 (0.74) | HSD11B1ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL13547706 | 0.78 | RORC (0.46) | HSD11B1ALDH1A1HSD17B10SMN1; SMN2MAPT | |
| SCHEMBL1703004 | 0.77 | ALDH1A1 (0.52) | ALDH1A1HSD17B10MAPTMEN1KMT2A | |
| SCHEMBL859415 | 0.75 | ALDH1A1 (0.74) | ALDH1A1HSD17B10SMN1; SMN2MAPTHPGD | |
| SCHEMBL1493589 | 0.74 | HSD11B1 (0.57) | HSD11B1ALDH1A1KMT2AHTTHDAC6 | |
| SCHEMBL10680419 | 0.74 | HSD11B1 (0.51) | HSD11B1ALDH1A1MAPT | |
| SCHEMBL1493557 | 0.73 | HSD11B1 (0.48) | HSD11B1MAPTHDAC6FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569919-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-04-14 | — | — | US | disclosed |
| EP-2288603-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2011-03-02 | — | — | EP | disclosed |
| US-7642277-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-05 | — | — | US | disclosed |
| WO-2009150614-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-12-17 | — | — | WO | disclosed |
| CN-1720043-A | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INT (DE) | 2006-01-11 | — | — | CN | disclosed |
| EP-1569919-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| US-20050054639-A1 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2004050643-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054639-A1 | Non-nucleoside reverse transcriptase inhibitors | NAT1, SUB1, RTF2 | HSD11B1 1036/4885ALDH1A1 1533/4885HSD17B10 669/4885 |
| US-20110086889-A1 | TETRAZOLE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | HSD11B1 1201/4885ALDH1A1 3233/4885HSD17B10 3334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.